NEW YORK, NY - (NewMediaWire) - February 27, 2024 - Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) reminds investors that a complaint has been filed on behalf of purchasers or acquirers of the common stock of iRhythm Technologies, Inc. (“iRhythm” or the “Company”) (NASDAQ: IRTC) between January 11, 2022 and May 30, 2023, inclusive (the “Class Period”).  iRhythm is a digital healthcare company that develops and manufactures heart monitoring devices designed to diagnose arrhythmias. Click Here to Join Investigation.

If you acquired iRhythm common stock during the Class Period and would like to discuss our investigation, please click here or contact us by emailing pmayer@kaplanfox.com or by calling (646) 315-9003.

On May 30, 2023, after the market closed, iRhythm disclosed the receipt of a warning letter from the Food and Drug Administration (“FDA”) that detailed several serious issues with the Zio AT device (the "Warning Letter"). Among other things, the Warning Letter criticized iRhythm's marketing of the Zio AT as a "mobile cardiac telemetry monitor" that provides "near real-time monitoring" and is approved for use in "high-risk patients" as false. According to the FDA, the Zio AT device was only approved for non-critical patients and suffered from critical flaws that imperiled high-risk patients.  For example, as alleged in the complaint, the Warning Letter revealed that the Zio AT has a data transmission limit and that iRhythm failed to communicate this to providers and end-users. Critically, once the transmission limit is reached, the patient's data stops being transmitted.

Following these disclosures, the price of iRhythm shares fell $7.41 per share, about 6.1%, to close at $114.27 per share on May 31, 2023.

If you are a member of the proposed Class, you may move the court no later than April 8, 2024 to serve as a lead plaintiff for the purported class.  If you have losses, we encourage you to contact us to learn more about the lead plaintiff process.

WHY CONTACT KAPLAN FOX - Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey.  With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand.  Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients.  For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com. 

If you have any questions about this Notice, your rights, or your interests, please contact:

Pamela A. Mayer

KAPLAN FOX & KILSHEIMER LLP
800 Third Avenue, 38th Floor
New York, New York 10022
(646) 315-9003

E-mail: pmayer@kaplanfox.com

Laurence D. King
KAPLAN FOX & KILSHEIMER LLP
1999 Harrison Street, Suite 1560
Oakland, California 94612
(415) 772-4704
Fax:  (415) 772-4707
E-mail: lking@kaplanfox.com